← Back to Search

Topical Dermatological Agent

ARQ-154 for Seborrheic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Arcutis Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights

Study Summary

This trial will study the long-term safety of a medication applied topically once daily for 52 weeks to people with seborrheic dermatitis, a skin condition.

Eligible Conditions
  • Seborrheic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serious Adverse Events
Treatment Emergent Adverse Events
Secondary outcome measures
Duration of Response
Investigator Global Assessment
Treatment Free Interval

Trial Design

1Treatment groups
Experimental Treatment
Group I: Long-term safety of ARQ-154Experimental Treatment1 Intervention
Open-label, Long-term Safety of ARQ-154
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARQ-154
2020
Completed Phase 2
~410

Find a Location

Who is running the clinical trial?

Arcutis Biotherapeutics, Inc.Lead Sponsor
21 Previous Clinical Trials
7,233 Total Patients Enrolled
2 Trials studying Seborrheic Dermatitis
683 Patients Enrolled for Seborrheic Dermatitis
David Berk, MDStudy DirectorArcutis Biotherapeutics
21 Previous Clinical Trials
8,227 Total Patients Enrolled
2 Trials studying Seborrheic Dermatitis
683 Patients Enrolled for Seborrheic Dermatitis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Michigan
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
2020. "Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04445987.
~84 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top